CMS 2008 Part D Formulary Review Policy Leaves More To Drug Firm, Health Plan Negotiations
This article was originally published in The Pink Sheet Daily
By allowing plans to leave off what is expected to be a small number of “key drug types,” CMS anticipates more robust negotiations, lower prices.
You may also be interested in...
Biden Administration’s regulatory freeze suspends HHS action to appoint an administrative dispute resolution board for the 340B program. Good news for manufacturers?
If not reversed by the Biden Administration, demo program that puts plans at increased risk in catastrophic phase would also enhance negotiating leverage for drugs in the protected classes.
Tactic aims to allow incoming Administration to scrutinize so-called ‘midnight rules’ issued in the final days of the Trump Administration before they take effect. Regulators may also solicit stakeholder comments on delayed rules.